Difference between revisions of "Ticagrelor (Brilinta)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 14: | Line 14: | ||
[[Category:P2Y12 ADP inhibitors]] | [[Category:P2Y12 ADP inhibitors]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2011]] |
Revision as of 19:01, 30 July 2018
General information
Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
History of changes in FDA indication
Note that this agent does not have a hematology-specific indication at this time.
- 7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
- 9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI).